Gilead Sciences Dirección
Dirección controles de criterios 3/4
El CEO de Gilead Sciences es Dan O'Day , nombrado en Mar 2019, tiene una permanencia de 5.67 años. compensación anual total es $22.61M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.04% de las acciones de la empresa, por valor de $44.74M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 6.5 años, respectivamente.
Información clave
Dan O'Day
Chief Executive Officer (CEO)
US$22.6m
Compensación total
| Porcentaje del salario del CEO | 7.7% |
| Permanencia del CEO | 5.7yrs |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | 4.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.5yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings
Nov 13
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Nov 07Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It
Oct 01Gilead Sciences: Buy This Bargain Before It's Gone
Aug 30Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
Aug 05A Look At Gilead Sciences After Its Recent Weakness
Jul 27Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Gilead Sciences: Realizing Financial Projections Is Key
Mar 20Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$126m |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$485m |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$5b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$4b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$5b |
| Mar 31 2021 | n/a | n/a | US$301m |
| Dec 31 2020 | US$19m | US$2m | US$123m |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | -US$257m |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$29m | US$1m | US$5b |
Compensación vs. Mercado: La compensación total de Dan($USD22.61M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD12.66M).
Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.
CEO
Dan O'Day (60 yo)
5.7yrs
Permanencia
US$22,607,690
Compensación
Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 5.7yrs | US$22.61m | 0.040% $ 44.7m | |
| Chief Financial Officer | 5yrs | US$8.11m | 0.011% $ 12.5m | |
| Executive VP of Corporate Affairs | 2.3yrs | US$5.27m | 0.0017% $ 1.9m | |
| Chief Commercial Officer | 5.3yrs | US$8.59m | 0.0059% $ 6.6m | |
| Chief Medical Officer | 5yrs | US$8.39m | 0.0080% $ 9.0m | |
| Senior VP | 1.7yrs | sin datos | 0.0029% $ 3.3m | |
| Vice President of Investor Relations | 3.8yrs | sin datos | sin datos | |
| Executive Vice President of Human Resources | 5.3yrs | sin datos | sin datos | |
| Senior Vice President of Research | 4.8yrs | sin datos | sin datos | |
| Senior Vice President of Commercial Operations of Australia | no data | sin datos | sin datos | |
| Executive Vice President of Research | 3.6yrs | sin datos | sin datos | |
| Senior Vice President & Therapeutic Area Head of Gilead Oncology | 3.3yrs | sin datos | sin datos |
4.8yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de GILD se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 5.7yrs | US$22.61m | 0.040% $ 44.7m | |
| Lead Independent Director | 4.1yrs | US$444.92k | 0.00082% $ 921.7k | |
| Member of Scientific Advisory Board | no data | US$16.00k | sin datos | |
| Independent Director | 6.8yrs | US$429.92k | 0.0020% $ 2.2m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6.5yrs | US$414.92k | 0.0010% $ 1.2m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 8.3yrs | US$434.92k | 0.00011% $ 123.6k | |
| Chairperson of Scientific Advisory Board | no data | sin datos | sin datos |
6.5yrs
Permanencia media
71yo
Promedio de edad
Junta con experiencia: La junta directiva de GILD se considera experimentada (6.5 años de antigüedad promedio).